New study shows how diabetes medication improves quality of life
最新研究顯示糖尿病藥物如何改善生活品質
更新於: 2026年6月4日 上午03:00
For years, diabetes management focused almost exclusively on blood sugar numbers and preventing long-term health complications.
多年來，糖尿病的管理幾乎完全聚焦於血糖數據以及預防長期的健康併發症。
However, a significant shift is occurring in how we measure success.
然而，我們衡量成功的標準正在發生重大的轉變。
Recent research, including the 2026 FLOW trial, highlights that diabetes treatment should also prioritize Health-Related Quality of Life (HRQOL).
近期的研究，包含2026年的FLOW試驗，強調了糖尿病治療也應優先考慮「健康相關生活品質」(HRQOL)。
This means looking at how a patient feels, their energy levels, mobility, and their ability to enjoy daily activities.
這意味著要關注病人的感覺、能量水平、行動能力，以及他們享受日常生活活動的能力。
In the FLOW trial, patients with type 2 diabetes and kidney disease who took once-weekly semaglutide reported better outcomes than those on a placebo.
在FLOW試驗中，患有第二型糖尿病與腎臟病的病人，在使用每週一次的semaglutide後，回報的成效優於使用安慰劑的對照組。
While different medications have varying impacts—ranging from metformin's endurance benefits to the precision of insulin analogs—the message is clear: the patient's daily experience matters as much as their lab results.
雖然不同的藥物有不同的影響——從二甲雙胍的耐受性益處，到胰島素類似物的精準度——但重點很明確：病人的日常體驗與他們的檢驗結果同樣重要。
By shifting from strictly preventative care to 'experiential medicine,' doctors can better support patients in maintaining their independence and social well-being.
透過從嚴格的預防性護理轉向「體驗醫學」，醫生能更好地協助病人維持其獨立性與社交幸福感。
Ultimately, a successful diabetes treatment plan is not just about numbers on a chart; it is about helping patients live their lives as comfortably and actively as possible.
最終，一個成功的糖尿病治療計畫不只是關於圖表上的數字；而是關於協助病人盡可能舒適且活躍地生活。
